Rohto Pharmaceutical Co.,Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales of JPY 218,000 million, operating income of JPY 28,000 million, profit attributable to owners of parent of JPY 19,500 million and net income per share of JPY 170.95.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,056 JPY | -3.84% | -0.33% | +6.75% |
Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.75% | 4.7B | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Rohto Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023